May 24, 2016 9:00 PM ET


Company Overview of Clearside BioMedical, Inc.

Company Overview

Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

1220 Old Alpharetta Road

Suite 300

Alpharetta, GA 30005

United States

Founded in 2011

21 Employees





Key Executives for Clearside BioMedical, Inc.

Chief Executive Officer, President and Director
Age: 47
Chief Financial Officer
Age: 50
Executive Vice President of Research and Development
Age: 49
Vice President of Research and Development
Age: 49
Vice President of Scientific Affairs and Member of The Scientific Advisory Board
Compensation as of Fiscal Year 2015.

Clearside BioMedical, Inc. Key Developments

Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion

Clearside Biomedical, Inc. announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint. In preliminary results from the trial, patients in the active arm (those receiving concomitant administration of ZUPRATA and EYLEA) qualified for approximately 60% fewer intravitreal EYLEA treatments than those patients in the control arm who initially received EYLEA alone, during the three-month observation period following initial treatment (p=0.013). The trial, known as Tanzanite, is the first controlled, masked, randomized clinical trial conducted in patients with RVO where drug was administered through the suprachoroidal space. Secondary endpoints in the trial included the mean change from baseline in best corrected visual acuity (BCVA) and central subfield thickness. For the BCVA endpoint, at month 1, patients in the active arm had an average improvement of approximately 16 letters in BCVA, or over three lines on a standard eye chart, compared to approximately 11 letters of improvement, or just over two lines, for patients in the control arm, each from their respective baseline measurements. At the end of the three-month observation period, patients in the active arm had an average improvement of approximately 19 letters, while patients in the control arm maintained their same level of improvement at approximately 11 letters. In the secondary objective of measuring the central subfield thickness, at month 1, patients in both arms showed a mean reduction of over 400 µm. Patients in the active arm maintained this level of reduction throughout the three-month trial, while patients in the control arm had smaller levels of reduction as the trial progressed, with the mean reduction declining to approximately 340 µm for patients in the control arm beginning in month 2. In terms of safety results, there were no serious adverse events reported in the trial, and the treatment was generally well tolerated. Clearside plans on submitting the full data set for presentation at an upcoming medical meeting.

Clearside Biomedical, Inc. Appoints Richard J. Croarkin to its Board of Directors

Clearside Biomedical, Inc. announced that Richard J. Croarkin has been appointed to Clearside’s Board of Directors. Mr. Croarkin is the former Senior Vice President of Finance, Chief Financial Officer & Corporate Strategy Officer of Alcon, Inc. Mr. Croarkin is currently a Director on the Board of Aerie Pharmaceuticals, Inc., which he joined in May 2015. Mr. Croarkin also serves as a panelist on the NASDAQ Listing Qualifications Panel.

Clearside Seeks Acquisitions

Clearside BioMedical, Inc., launched the initial public offering of $57.5 million, net proceeds from the issuance, in the ordinary course of our business, expect to from time to time evaluate the acquisition, investment in or in-license of complementary products, technologies or businesses, and could use a portion of the net proceeds from this offering for such activities. Clearside BioMedical currently do not have any agreements, arrangements or commitments with respect to any potential acquisition, investment or license.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Private Placement
November 23, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Clearside BioMedical, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at